B2i Digital

Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Dr. Shalabh Gupta, MD will be presenting at two September investor conferences. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/eg9U-h4f. - Event: H.C. Wainwright 27th Annual Global Investment Conference, Type: Fireside chat, Date/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET - Event: Truist Securities Virtual Fireside Chat, Date/Time: Wednesday, September 17, 2025, at 10 a.m. ET Live and archived webcasts will be available through the Events and Presentations section on Unicycive’s investor website. Conference representatives can arrange one-on-one meetings for investors with Unicycive’s management upon request. Unicycive Therapeutics develops clinical-stage treatments for kidney disease patients. The company’s lead candidate, oxylanthanum carbonate, is a phosphate-binding agent under FDA review for treating hyperphosphatemia in dialysis patients with chronic kidney disease. Their second program, UNI-494, addresses acute kidney injury-related conditions and has FDA orphan drug designation for preventing delayed graft function in kidney transplant recipients. The company’s experienced leadership includes CEO Dr. Shalabh Gupta, MD, CFO John Townsend, EVPs Doug Jermasek and Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, all focused on addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/). Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

Spartan Capital Securities, LLC and B2i Digital are pleased to announce that Anixa Biosciences, Inc. (NASDAQ: ANIX) will be a presenting company at the upcoming Spartan Capital Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference. Now in its second year, the conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital. Investors can register to attend: https://lnkd.in/g8Y249nF. Event details and registration are available at https://lnkd.in/edsVSMsh. Anixa Biosciences, Inc. is a clinical-stage biotechnology company developing first-in-class products for cancer treatment and prevention. The Company’s therapeutic portfolio includes an ovarian cancer CAR-T immunotherapy program being developed with Moffitt Cancer Center. Its vaccine portfolio features programs in collaboration with Cleveland Clinic targeting breast and ovarian cancers, plus additional vaccines addressing lung, colon, and prostate cancers. With positive Phase 1 clinical data showing over 70% immune response rates in breast cancer vaccine trials and no dose-limiting toxicities in ovarian cancer CAR-T therapy, Anixa continues advancing its robust oncology pipeline under the leadership of Chairman and CEO Dr. Amit Kumar, President and COO/CFO Mike Catelani, and Chief Development Officer Dr. Pamela Garzone. B2i Digital is working closely with the outstanding Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach.Learn more about Anixa Biosciences at https://anixa.com.

Join partner and chair of HSE's Privacy and Data Security, Artificial Intelligence and New Technologies practice groups, Francis Paul Greene, at The Business of Banking Conference on Tuesday, September 30 for his insightful presentation, "Crafting the AI Policy". I'll be in the audience for this one with Alexander McClean, so find me if you're going to be at this conference! Learn more: https://lnkd.in/grVcxDes

Join ROTH Capital Partners and our sustainability team including Jesse P., Robert Stephenson, Philip Shen, Craig Irwin, Chip Moore, CFA, Justin Clare, CFA, Gerry Sweeney and more at RE+ for the largest and most comprehensive event in North America for the clean energy industry. For registration and information on the ROTH Symposium. #roth.com/re+2025

Spartan Capital Securities, LLC and B2i Digital are pleased to announce that Vizsla Royalties. (TSXV: VROY) (OTCQB: VROYF) will be a presenting company at the upcoming Spartan Capital Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Securities Investor Conference 2025 is a B2i Digital Featured Conference. Now in its second year, the conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital. Event details and registration are available at https://lnkd.in/edsVSMsh. B2i Digital is working closely with the outstanding Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach. Investors can register to attend: https://lnkd.in/g8Y249nF. Vizsla Royalties Corp. is a precious metals focused royalty company. The Company’s principal asset is a Net Smelter Return Royalty on Vizsla Silver Corp.’s (TSX: VZLA, NYSE: VZLA) flagship Panuco Project located in Mexico, giving investors exposure to future silver and gold production without direct operating risk. Panuco is a world-class silver and gold development project actively advancing towards production. A Preliminary Economic Study for Panuco was published in July 2024 which highlights 15.2 Moz AgEq of annual production over an initial 10.6-year mine life, an after-tax NPV5% of US$1.1B, 86% IRR and a 9-month payback at US$26/oz Ag and US$1,975/oz Au. Learn more about Vizsla Royalties at https://lnkd.in/eMxMvVWN.

Xtant Medical Holdings (NYSE-American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, reported Second Quarter 2025 financial results, including total revenue of $35.4 Million, up 18% Year-over-Year. Xtant Medical is a B2i Digital Featured Company. View the comprehensive profile at https://lnkd.in/e7SSh3RR. Additional highlights reported in the company’s Q2 2025 earnings release were: • Gross margin of 68.6% compared to 62.1% for the prior year quarter. • Net income of $3.6 million compared to a net loss of $3.9 million in the prior year quarter. • Adjusted EBITDA of $6.9 million compared to Adjusted EBITDA loss of $0.6 million in the prior year quarter. • Cash and cash equivalents of $6.9 million as of June 30, 2025. Sean Browne, President and CEO of Xtant Medical, noted in the release, “We delivered strong financial and operating results during the second quarter, reflecting steps taken to enhance our focus on our core biologics business while also prudently managing expenses across the organization and driving operating leverage, consistent profitability, and cash flow. Notably, with the recent launch of our next-generation growth factor, OsteoFactor Pro™, we are now the only vertically integrated company to develop and manufacture solutions across all major orthobiologic categories. Our recently announced agreements to sell certain non-core spinal implant and OUS businesses to Companion Spine represent another step toward the realization of our strategic vision for the company. Once completed, this transaction will allow us to significantly strengthen our balance sheet and further support the ongoing development of our broad pipeline of advanced biologics. I believe our tireless commitment to innovation and quality uniquely positions Xtant to address the needs of surgeons and patients alike while simultaneously creating enduring value for our shareholders.” See the full news release at: https://lnkd.in/eRxXxYDX A replay of the quarterly conference call featuring President & CEO Sean Browne and CFO Scott Neils is available on the Investor section of the Company’s website at www.xtantmedical.com. The company is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils, and Chief Operating Officer Mark Schallenberger, whose collective experience spans medical-device commercialization, corporate finance, and orthobiologic innovation. For more information, visit https://lnkd.in/etF3qHWF. Investor inquiries: Kevin Gardner at LifeSci Advisors, kgardner@lifesciadvisors.com.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) (Nasdaq: INBS) announced its highest-ever monthly cartridge sales for July 2025, with a record 519 boxes shipped, representing over 12,500 cartridges and a 60% year-over-year increase. Intelligent Bio Solutions is a B2i Digital Featured company. View INBS’s comprehensive profile at https://lnkd.in/gCF9hkFm. The company’s higher-margin cartridge consumables are central to its razor/razor blade business model for fingerprint sweat-based drug testing. Recent contract wins, including a multi-site, high-volume deployment in the transportation sector, have accelerated this recurring revenue stream. As INBS expands its global installed base, consumable demand continues to rise. The company reports strong momentum with a robust pipeline and increasing participation in bids and tenders for large-scale implementations. Commenting on the results, Harry Simeonidis, President & CEO of Intelligent Bio Solutions, stated: “July’s record cartridge sales show the strength of our razor/razor blade business model and the momentum generated by major contract wins. As we expand our installed base and win larger opportunities, we see continued growth in cartridge demand, delivering attractive margins and a reliable revenue stream.” INBS noted it remains focused on leveraging its installed base to drive recurring consumable sales while preparing for U.S. market expansion beyond Forensic Use Only settings in the second half of 2025. See the full release at: https://lnkd.in/epMRcUd7. Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is advancing hygienic, rapid, and cost-effective fingerprint sweat-based testing worldwide. The company’s non-invasive, patented technology delivers results in under ten minutes and now supports more than 450 accounts across 24 countries in the workplace safety, law enforcement, drug treatment, and forensics markets. Its experienced global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli MBus, and Peter Passaris. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at INBS@kcsa.com, KCSA Strategic Communications. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted INBS stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of INBS or any security, and it is not intended to offer any opinion on INBS as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

🌍 From core operations to new initiatives, Heidmar’s roadmap shows how the company is building sustainable momentum.   💬 CEO Pankaj Khanna discusses how strategic acquisitions, new market entries, and expanded capabilities are setting the stage for long-term value creation. ⚙️ Find out how this one-stop maritime solutions provider is positioning for what’s next. ⚓ Heidmar Inc. Q2 2025: Strengthening Core Operations and Launching New Initiatives. 💡 📽️ Watch discussion here: https://lnkd.in/dkxHD2YE #shipping #maritime #ceo #shipmanagement #pooloperator

Applied Energetics, Inc. (OTCQB: AERG), a leader in ultrashort pulse laser technology and advanced directed energy solutions, achieved a major milestone today with the first live multi-drone camera kills using its prototype Pulsed Laser Air Defense (PLAID™) gimbal. Applied Energetics is a B2i Digital Featured Company. View its profile at https://lnkd.in/eVEkcBCH. BIG DAY today in the Applied Energetics Battle Lab! The team successfully demonstrated first multi-drone camera kills — four drones, four disabled cameras in just four seconds — using our early prototype Pulsed Laser Air Defense (PLAID™) gimbal. What you’re seeing in this demonstration: - Objects 2, 3, and 4 were FPV drones with active cameras. - Object 1 was a stand-alone camera coupled to a transmitter but not mounted on a drone. - The poor image quality in objects 2, 3, and 4 resulted from close transmitter proximity causing signal interference. - The first image comes from a video captured by the Kord Firefly narrow field-of-view camera, with the laser illuminating object 2. Applied Energetics continues to leverage its portfolio of 27 issued patents and 7 pending patents to advance next-generation defense and dual-use applications, especially fiber-based ultrashort pulse (USP) laser technologies. Learn more about Applied Energetics: https://lnkd.in/eBWivN8E Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted AERG stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of AERG or any security, and it is not intended to offer any opinion on AERG as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m

BIG DAY today in the Applied Energetics, Inc. Battle Lab! First multi-drone camera kills. Four drones, four dead cameras in four seconds through our early prototype Pulsed Laser Air Defense gimbal! #USPL #CUAS